Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts This week, 27 April 2025: Treatment-resistant hypertension Influenza transmission Nanoplastics in human brains Malaria elimination Chikungunya vaccine

Prostate Cancer

Free Subscription Articles published in Eur Urol Retrieve available abstracts of 214 articles: HTML format

Single Articles

May 2025
1. PLOUSSARD G, Coloby P, Chevallier T, Occean BV, et al
   Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.
   Eur Urol. 2025;87:526-533.
   PubMed     Abstract available
   
   
   April 2025
2. GOMEZ RIVAS J, Moreno Sierra J
   Re: Darolutamide in Combination with Androgen-deprivation Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer from the Phase III ARANOTE Trial.
   Eur Urol. 2025 Apr 23:S0302-2838(25)00208-8. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
3. GOMEZ RIVAS J, Moreno Sierra J
   Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
   Eur Urol. 2025 Apr 22:S0302-2838(25)00207-6. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
4. VICKERS A, Touijer K
   Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2024;86:148-63.
   Eur Urol. 2025 Apr 12:S0302-2838(25)00200-3. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
5. ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al
   Corrigendum to "Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial" [Eur. Urol. 86 (2024) 552-562
   Eur Urol. 2025 Apr 8:S0302-2838(25)00179-4. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
6. CHEN S, Xu H, Chen X, Shen Q, et al
   First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen-targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer.
   Eur Urol. 2025 Apr 8:S0302-2838(25)00182-4. doi: 10.1016/j.eururo.2025.
   PubMed     Abstract available
   
   
   
7. ROBERTS MJ, Gandaglia G, Oprea-Lager DE, Stranne J, et al
   Pelvic Lymph Node Dissection in Prostate Cancer: Evidence and Implications.
   Eur Urol. 2025 Apr 7:S0302-2838(25)00154-X. doi: 10.1016/j.eururo.2025.
   PubMed     Abstract available
   
   
   March 2025
8. MAZZONE E, Cannoletta D, Quarta L, Chen DC, et al
   A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment.
   Eur Urol. 2025 Mar 27:S0302-2838(25)00155-1. doi: 10.1016/j.eururo.2025.
   PubMed     Abstract available
   
   
   
9. MONTORSI F, Gandaglia G, Barletta F, Briganti A, et al
   Re: Andreas Josefsson, Marianne Mansson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial. Eur Urol 2024;86:223-9.
   Eur Urol. 2025 Mar 26:S0302-2838(25)00124-1. doi: 10.1016/j.eururo.2025.
   PubMed    
   
   
   
10. SHAH RB, Paner GP, Cheng L, De Marzo AM, et al
    Genitourinary Pathology Society and International Society of Urological Pathology White Paper on Defining Indolent Prostate Cancer: Call for a Multidisciplinary Approach.
    Eur Urol. 2025 Mar 17:S0302-2838(25)00150-2. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
11. HAGE CHEHADE C, Ozay ZI, Ostrowski M, Mercinelli C, et al
    T-cell Engagers in Prostate Cancer.
    Eur Urol. 2025 Mar 11:S0302-2838(25)00070-3. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
12. DEVOS G, Giesen A, Joniau S
    When Less Is More: The Challenges of Defining Residual Disease Following Neoadjuvant Hormonal Therapy in Prostate Cancer.
    Eur Urol. 2025 Mar 10:S0302-2838(25)00146-0. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
13. TAHA T, Koster KL, de Bono JS
    T-Cell Engagers in Prostate Cancer: Promise, Challenges, and the Road Ahead.
    Eur Urol. 2025 Mar 5:S0302-2838(25)00147-2. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
14. GILLESSEN S, Tombal B, Turco F, Choudhury A, et al
    Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis.
    Eur Urol. 2025;87:285-288.
    PubMed     Abstract available
    
    
    February 2025
15. FREEDLAND SJ, Mulhall JP, Gleave M, Giorgi U, et al
    Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study.
    Eur Urol. 2025 Feb 26:S0302-2838(25)00094-6. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
16. AZAD AA, Kostos L, Agarwal N, Attard G, et al
    Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer.
    Eur Urol. 2025 Feb 12:S0302-2838(25)00023-5. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
17. RAVI P, Kwak L, Acosta AM, Rastogi S, et al
    Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer.
    Eur Urol. 2025 Feb 6:S0302-2838(25)00027-2. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
18. CASTRO E, Lorente D, Olmos D
    PARP Inhibitors and Prostate Cancer: The Struggle To Separate the Grain from the Chaff.
    Eur Urol. 2025 Feb 3:S0302-2838(25)00024-7. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
19. MORGAN TM, Daignault-Newton S, Spratt DE, Dunn RL, et al
    Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.
    Eur Urol. 2025;87:228-237.
    PubMed     Abstract available
    
    
    January 2025
20. BERNARDINO RM, van der Kwast T, Fleshner NE
    Intraductal Carcinoma and Cribriform Pattern in Prostate Cancer: Challenges and Emerging Perspectives.
    Eur Urol. 2025 Jan 30:S0302-2838(25)00025-9. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
21. NAQVI SAA, Riaz IB, Bibi A, Khan MA, et al
    Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.
    Eur Urol. 2025 Jan 22:S0302-2838(24)02760-X. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
22. MURTHY V, Marvaso G, Jereczek-Fossa BA, Thoma SA, et al
    The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care.
    Eur Urol. 2025 Jan 20:S0302-2838(25)00008-9. doi: 10.1016/j.eururo.2025.
    PubMed     Abstract available
    
    
    
23. LONGONI M, Briganti A, Gandaglia G, Montorsi F, et al
    Re: Metastatic Hormone-sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.
    Eur Urol. 2025 Jan 10:S0302-2838(25)00001-6. doi: 10.1016/j.eururo.2025.
    PubMed    
    
    
    
24. LEENEN RCA, Roobol MJ, Beyer K
    Reply to Jonas Hugosson. Population-based Screening for Prostate Cancer: Is It Time? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.003.
    Eur Urol. 2025 Jan 4:S0302-2838(24)02767-2. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
25. EL-TAJI O, Clarke NW
    Balancing Efficacy and Cardiotoxicity in Prostate Cancer Therapy: A Call for Precision in Treatment Strategies.
    Eur Urol. 2025;87:27-28.
    PubMed    
    
    
    
26. ONG WL, Romero T, Roy S, Nikitas J, et al
    Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.
    Eur Urol. 2025;87:49-57.
    PubMed     Abstract available
    
    
    December 2024
27. STRANNE J, Henry A, Oprea-Lager DE
    Use of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Nodal Staging in Prostate Cancer and Tailoring of Treatment: A Continuing Conundrum.
    Eur Urol. 2024 Dec 18:S0302-2838(24)02745-3. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
28. TISSEVERASINGHE S, Tolba M, Saad F, Fizazi K, et al
    Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
    Eur Urol. 2024 Dec 17:S0302-2838(24)02748-9. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
29. DIAS AB, Moore CM, Renard-Penna R, Giganti F, et al
    Biparametric Versus Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Choice or a Fine Balance?
    Eur Urol. 2024 Dec 16:S0302-2838(24)02740-4. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
30. DAVIS JW
    Multiparametric Magnetic Resonance Imaging with Targeted-only Biopsy-A New Standard for Guidelines on Prostate Cancer Detection?
    Eur Urol. 2024 Dec 11:S0302-2838(24)02717-9. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
31. SCHAFER EJ, Laversanne M, Sung H, Soerjomataram I, et al
    Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update.
    Eur Urol. 2024 Dec 5:S0302-2838(24)02707-6. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    November 2024
32. MADEC FX, Mesnard B, Dariane C
    Re: Prevalence and Factors Associated with Prostate Cancer Among Transgender Women.
    Eur Urol. 2024 Nov 21:S0302-2838(24)02704-0. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
33. COOPERBERG MR
    Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
    Eur Urol. 2024 Nov 21:S0302-2838(24)02700-3. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
34. HUGOSSON J
    Population-based Screening for Prostate Cancer: Is it Time?
    Eur Urol. 2024 Nov 20:S0302-2838(24)02696-4. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
35. DAHM P, Wilt TJ
    Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
    Eur Urol. 2024 Nov 15:S0302-2838(24)02687-3. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
36. KISHAN AU, Lamb JM, Wilhalme H, Casado M, et al
    Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.
    Eur Urol. 2024 Nov 12:S0302-2838(24)02688-5. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
37. GHADJAR P, Zips D
    Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial.
    Eur Urol. 2024 Nov 12:S0302-2838(24)02691-5. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
38. ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
    Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [
    Eur Urol. 2024 Nov 8:S0302-2838(24)02684-8. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
39. PARKER CC, Clarke NW, Cook AD, Petersen PM, et al
    Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047).
    Eur Urol. 2024;86:422-430.
    PubMed     Abstract available
    
    
    
40. LANE BR, Dess RT, Borza T
    More Than Words: Defining Adjuvant, Consolidative, and Salvage Treatment after Radical Prostatectomy.
    Eur Urol. 2024;86:385-387.
    PubMed     Abstract available
    
    
    October 2024
41. OH WK, Agarwal N, Bryce A, Barata P, et al
    What's in a Name? Why Words Matter in Advanced Prostate Cancer.
    Eur Urol. 2024 Oct 28:S0302-2838(24)02680-0. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
42. TOUIJER KA, Vertosick EA, Sjoberg DD, Liso N, et al
    Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection.
    Eur Urol. 2024 Oct 28:S0302-2838(24)02647-2. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
43. TWILT JJ, Saha A, Bosma JS, van Ginneken B, et al
    Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study.
    Eur Urol. 2024 Oct 21:S0302-2838(24)02640-X. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
44. VANDERWEELE DJ, Hussain M
    Management Decisions for Metastatic Castration-resistant Prostate Cancer in 2024.
    Eur Urol. 2024 Oct 19:S0302-2838(24)02646-0. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
45. EVANGELISTA L, Cecchi L, Zucali PA
    Advancing Prostate Cancer Care: Prostate-specific Membrane Antigen-based Radioligand Therapy at the Forefront.
    Eur Urol. 2024 Oct 19:S0302-2838(24)02645-9. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
46. FENDLER WP, Grunwald V, Herrmann K, Hadaschik BA, et al
    Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer.
    Eur Urol. 2024 Oct 19:S0302-2838(24)02648-4. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
47. GILLESSEN S, Turco F, Davis ID, Efstathiou JA, et al
    Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
    Eur Urol. 2024 Oct 10:S0302-2838(24)02610-1. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
48. BAKHT MK, Beltran H
    Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naive Prostate Cancer.
    Eur Urol. 2024 Oct 10:S0302-2838(24)02637-X. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
49. ONG WL, Loblaw A
    Radiotherapy for Unfavorable-risk Prostate Cancer: Biologic Dose Escalation, Fewer Fractions, or Both?
    Eur Urol. 2024 Oct 9:S0302-2838(24)02636-8. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
50. ROUVIERE O, van Leenders GJLH, Eberli D
    Systematic Prostate Biopsy Versus Perilesional Sampling: If It Isn't Broke, Why Fix It?
    Eur Urol. 2024;86:295-296.
    PubMed     Abstract available
    
    
    
51. BROWN JR, Sonpavde GP, Calaway A, Barata PC, et al
    Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?
    Eur Urol. 2024;86:312-314.
    PubMed    
    
    
    
52. CIMADAMORE A, Giannarini G, Crestani A, Lopez-Beltran A, et al
    How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the "Tertiary" Terminology?
    Eur Urol. 2024;86:291-294.
    PubMed     Abstract available
    
    
    September 2024
53. GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
    Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer.
    Eur Urol. 2024 Sep 26:S0302-2838(24)02613-7. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
54. CARLSSON SV, Lilja H, Vickers AJ, Bjartell AS, et al
    Re: Early Prostate Cancer Deaths Among Men with Higher vs Lower Genetic Risk.
    Eur Urol. 2024 Sep 25:S0302-2838(24)02615-0. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
55. QI F
    Re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer
    Eur Urol. 2024 Sep 25:S0302-2838(24)02612-5. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
56. VAN DEN BERGH RCN, Schoots IG, Cornford PA
    Standard Repeat Biopsies During Active Surveillance for Prostate Cancer: Are They Necessary in the Magnetic Resonance Imaging Era?
    Eur Urol. 2024 Sep 25:S0302-2838(24)02607-1. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
57. DAI YH, Chen PH, Lee DJ, Andrade G, et al
    A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer.
    Eur Urol. 2024 Sep 25:S0302-2838(24)02608-3. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
58. RATHKOPF DE, Roubaud G, Chi KN, Efstathiou E, et al
    Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
    Eur Urol. 2024 Sep 23:S0302-2838(24)02594-6. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
59. UNTERRAINER M, Unterrainer LM, Ilhan H
    Re: Robert Seifert, Louise Emmett, Steven P. Rowe, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol 2023;83:405-12.
    Eur Urol. 2024 Sep 23:S0302-2838(24)02617-4. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
60. KLUMPER N, Eckstein M
    Reply to Feng Qi's Letter to the Editor re: Niklas Klumper, Viktor Grunwald, Arndt Hartmann, et al. The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy
    Eur Urol. 2024 Sep 23:S0302-2838(24)02616-2. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
61. CHEN DC, Thomson A, Mazzone E, Perera ML, et al
    Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    Eur Urol. 2024 Sep 20:S0302-2838(24)02513-2. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
62. FRANCINI E, Agarwal N, Castro E, Cheng HH, et al
    Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review.
    Eur Urol. 2024 Sep 20:S0302-2838(24)02599-5. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
63. BOEVE LMS, Hulshof MCCM, Verhagen PCMS, Twisk JWR, et al
    Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.
    Eur Urol. 2024 Sep 19:S0302-2838(24)02593-4. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
64. AZIZ MK, Molony D, Monlezun D, Holder T, et al
    Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-analysis with Bayesian Modeling of Treatment Histories.
    Eur Urol. 2024 Sep 18:S0302-2838(24)02569-7. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
65. WEINER AB, Agrawal R, Wang NK, Sonni I, et al
    Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naive Prostate Cancer.
    Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
66. BJERNER J, Bratt O, Aas K, Albertsen PC, et al
    Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu's Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the No
    Eur Urol. 2024 Sep 17:S0302-2838(24)02575-2. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
67. BRATT O
    Prostate Cancer Screening: Setting the Controls on the Mixing Board.
    Eur Urol. 2024 Sep 17:S0302-2838(24)02598-3. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
68. NIAZI T, Nabid A, Malagon T, Tisseverasinghe S, et al
    Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Genito-urinaire du Quebec-led Phase 3 Trial.
    Eur Urol. 2024 Sep 12:S0302-2838(24)02574-0. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
69. VAN AS N, Yasar B, Griffin C, Patel J, et al
    Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.
    Eur Urol. 2024 Sep 11:S0302-2838(24)02568-5. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
70. LI R, Peng L, Zhang S, Wu S, et al
    Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol 2024;86:20-6.
    Eur Urol. 2024 Sep 5:S0302-2838(24)02564-8. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
71. ARMSTRONG AJ, Sartor O, de Bono J, Chi K, et al
    Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial.
    Eur Urol. 2024 Sep 5:S0302-2838(24)02560-0. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
72. NAIR SS, Muhammad H, Jain P, Xie C, et al
    A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.
    Eur Urol. 2024 Sep 3:S0302-2838(24)02496-5. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
73. KASIVISVANATHAN V, Wai-Shun Chan V, Clement KD, Levis B, et al
    VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer.
    Eur Urol. 2024 Sep 3:S0302-2838(24)02559-4. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
74. VYNCKIER P, Annemans L, Roobol M
    Reply to Andres Gutierrez, Julio Cesar Boada, and Sebastian Pena's Letter to the Editor re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost-effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. ht
    Eur Urol. 2024 Sep 2:S0302-2838(24)02566-1. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
75. ACHARD V, Tombal B
    All Biochemical Recurrences Are Equal, but Some Are More Equal than Others.
    Eur Urol. 2024;86:211-212.
    PubMed    
    
    
    August 2024
76. GUTIERREZ A, Boada JC, Pena S
    Re: Pieter Vynckier, Lieven Annemans, Sarah Raes, et al. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.04.036.
    Eur Urol. 2024 Aug 30:S0302-2838(24)02565-X. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
77. LEENEN RCA, Venderbos LDF, Helleman J, Gomez Rivas J, et al
    Prostate Cancer Early Detection in the European Union and UK.
    Eur Urol. 2024 Aug 24:S0302-2838(24)02502-8. doi: 10.1016/j.eururo.2024.
    PubMed     Abstract available
    
    
    
78. QI F
    Re: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter R
    Eur Urol. 2024 Aug 21:S0302-2838(24)02557-0. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
79. MAY M, Albersen M, Brookman-May S
    Re: Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
    Eur Urol. 2024 Aug 19:S0302-2838(24)02552-1. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
80. BRATT O
    Re: Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
    Eur Urol. 2024 Aug 17:S0302-2838(24)02523-5. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
81. CHEN DC, Park H, McVey A, Lawrentschuk N, et al
    Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study.
    Eur Urol. 2024 Aug 17:S0302-2838(24)02520-X. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
82. GORADIA R, Abdollah F, Sood A
    Re: Integrative Multi-Region Molecular Profiling of Primary Prostate Cancer in Men with Synchronous Lymph Node Metastasis.
    Eur Urol. 2024 Aug 6:S0302-2838(24)02497-7. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
83. KAMRAN SC, Efstathiou JA
    Honing Stratification and Treatment for High-risk Prostate Cancer.
    Eur Urol. 2024 Aug 6:S0302-2838(24)02489-8. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
84. DI LORENZO G, Buonerba C
    Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
    Eur Urol. 2024 Aug 1:S0302-2838(24)02500-4. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
85. THOMPSON IM JR
    Prostate-specific Antigen Screening in Limbo: How Low Should We Go?
    Eur Urol. 2024;86:101-102.
    PubMed    
    
    
    
86. MARRA G, Oderda M, Gontero P
    Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
    Eur Urol. 2024;86:e36-e37.
    PubMed    
    
    
    July 2024
87. MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al
    Re: Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Eur Urol. 2024 Jul 31:S0302-2838(24)02492-8. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
88. PARK H, Chen DC, Mazzone E, Grummet J, et al
    Re: Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening. The STHLM3-MRI Randomized Clinical Trial.
    Eur Urol. 2024 Jul 19:S0302-2838(24)02452-7. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
89. MAZZONE E, Perera S, Neti AL, Chen DC, et al
    Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
    Eur Urol. 2024 Jul 19:S0302-2838(24)02450-3. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
90. SPRATT DE, Liu VYT, Jia AY, Royce TJ, et al
    Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials.
    Eur Urol. 2024 Jul 17:S0302-2838(24)02454-0. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
91. HU JC, Schaeffer EM, Vickers AJ
    Reply to Ilias Giannakodimos' Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREV
    Eur Urol. 2024;86:e13.
    PubMed    
    
    
    
92. ROSEN GH, Chakiryan NH, Murray KS
    Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
    Eur Urol. 2024;86:e14.
    PubMed    
    
    
    
93. GIANNAKODIMOS I
    Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61-68.
    Eur Urol. 2024;86:e12.
    PubMed    
    
    
    
94. CHIU PK, Wu X, Gandaglia G
    Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate Biopsies.
    Eur Urol. 2024;86:e16-e17.
    PubMed    
    
    
    
95. HU JC, Assel M, Allaf ME, Ehdaie B, et al
    Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.
    Eur Urol. 2024;86:61-68.
    PubMed     Abstract available
    
    
    June 2024
96. TANEJA SS
    Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic Resonance Imaging-targeted Biopsy on Prostate Cancer Mortality?
    Eur Urol. 2024 Jun 19:S0302-2838(24)02413-8. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
97. COOPERBERG MR
    PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
    Eur Urol. 2024 Jun 18:S0302-2838(24)02400-X. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
98. SRIVASTAVA A, Lewicki P, Morgan TM
    Biomarkers in Prostate Cancer Screening: Sometimes "More is More".
    Eur Urol. 2024 Jun 18:S0302-2838(24)02428-X. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
99. RAYCHAUDHURI R, DeJong M, Rettig M, Yu EY, et al
    Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Recombination DNA Repair Pathway: The ABCD Trial.
    Eur Urol. 2024 Jun 17:S0302-2838(24)02407-2. doi: 10.1016/j.eururo.2024.
    PubMed    
    
    
    
100. MACEK P, Rodriguez-Sanchez L, Cathelineau X
     Re: Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of
     Eur Urol. 2024 Jun 13:S0302-2838(24)02401-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
101. ADELEKE S
     High-performing, Accessible, and Affordable Imaging in Metastatic Prostate Cancer: Is Whole-body Magnetic Resonance Imaging the Answer?
     Eur Urol. 2024 Jun 12:S0302-2838(24)02410-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     May 2024
102. VICKERS AJ
     Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
     Eur Urol. 2024 May 25:S0302-2838(24)02385-6. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
103. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
     Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Roder's Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer L
     Eur Urol. 2024 May 24:S0302-2838(24)02387-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
104. ULERI A, Baboudjian M, Diamand R, Ploussard G, et al
     Reply to Andrew J. Vickers' Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In
     Eur Urol. 2024 May 24:S0302-2838(24)02386-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
105. VYNCKIER P, Annemans L, Raes S, Amrouch C, et al
     Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
     Eur Urol. 2024 May 23:S0302-2838(24)02378-9. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
106. WEINER AB, Kakani P, Armstrong AJ, Bossi A, et al
     Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review.
     Eur Urol. 2024 May 22:S0302-2838(24)02375-3. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
107. RAVI P, Xie W, Buyse M, Halabi S, et al
     Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials.
     Eur Urol. 2024 May 21:S0302-2838(24)02380-7. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
108. DALLA VOLTA A, Valcamonico F, Zivi A, Procopio G, et al
     Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
     Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
109. JOSEFSSON A, Mansson M, Kohestani K, Spyratou V, et al
     Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GOTEBORG-2 Prostate Cancer Screening Trial.
     Eur Urol. 2024 May 20:S0302-2838(24)02379-0. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
110. BROOKMAN-MAY SD, Buyse M, Freedland SJ, Miladinovic B, et al
     Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer.
     Eur Urol. 2024 May 17:S0302-2838(24)02348-0. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
111. PADHANI AR, Lecouvet F, Petralia G, Koh DM, et al
     Re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. http
     Eur Urol. 2024 May 16:S0302-2838(24)02377-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
112. GARCIA-RUIZ A, Macarro C, Mateo J, Perez-Lopez R, et al
     Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castrati
     Eur Urol. 2024 May 16:S0302-2838(24)02376-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
113. FANKHAUSER CD, Wettstein MS, Wurnschimmel C, van Smeden M, et al
     Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
     Eur Urol. 2024 May 15:S0302-2838(24)02340-6. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
114. KRILAVICIUTE A, Kaaks R, Seibold P, de Vrieze M, et al
     Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
     Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
115. STROOMBERG HV, Brasso K, Roder A
     Re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.0
     Eur Urol. 2024 May 14:S0302-2838(24)02365-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
116. MERSEBURGER AS, Chowdhury S, Bahl A
     Therapy Optimization in the Management of Metastatic Hormone-sensitive Prostate Cancer: Insights from the ARASENS Study.
     Eur Urol. 2024 May 14:S0302-2838(24)02364-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
117. CHIN JL
     Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database.
     Eur Urol. 2024 May 13:S0302-2838(24)02344-3. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
118. KLUMPER N, Grunwald V, Hartmann A, Holzel M, et al
     The Role of Microsatellite Instability/DNA Mismatch Repair Deficiency and Tumor Mutational Burden as Biomarkers in Predicting Response to Immunotherapy in Castration-resistant Prostate Cancer.
     Eur Urol. 2024 May 13:S0302-2838(24)02350-9. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
119. OKOLI S, Okoli O, Ding H, Adeleke S, et al
     Re: Actinium-225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer (WARMTH Act): A Multicentre, Retrospective Study.
     Eur Urol. 2024 May 11:S0302-2838(24)02352-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
120. LIGHT A, Mayor N, Cullen E, Kirkham A, et al
     The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
     Eur Urol. 2024;85:466-482.
     PubMed     Abstract available
     
     
     
121. ANAND M, Jain B, Aggarwal S
     Re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
     Eur Urol. 2024;85:e145.
     PubMed    
     
     
     
122. HARTRAMPF PE, Rowe SP, Pomper MG, Higuchi T, et al
     Reply to Madhur Anand, Bela Jain, and Swati Aggarwal's Letter to the Editor re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-Specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491-502.
     Eur Urol. 2024;85:e146-e147.
     PubMed    
     
     
     April 2024
123. TILKI D, van den Bergh RCN, Briers E, Van den Broeck T, et al
     EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
     Eur Urol. 2024 Apr 29:S0302-2838(24)02306-6. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
124. OST P, Siva S, Zilli T
     OLIGOPELVIS and the "All You Can Eat" Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full?
     Eur Urol. 2024 Apr 27:S0302-2838(24)02307-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
125. HU JC, Vickers AJ, Schaeffer EM
     Reply to Peter Ka-Fung Chiu, Xiaobo Wu, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Beyond Statistical Significance: Unveiling the Advantages of Transperineal Versus Transrectal Prostate
     Eur Urol. 2024 Apr 26:S0302-2838(24)02314-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
126. CHAKRABARTI D, Parker CC
     Metastatic Hormone-sensitive Prostate Cancer: Patient Selection for Prostate Radiotherapy.
     Eur Urol. 2024 Apr 26:S0302-2838(24)02308-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
127. SAAD F, Hussain MHA, Tombal B, Fizazi K, et al
     Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of
     Eur Urol. 2024 Apr 20:S0302-2838(24)02264-4. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
128. HINDIE E, Champion C, Morgat C
     Re: Renu S. Eapen, James P. Buteau, Price Jackson, et al. Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. In press.
     Eur Urol. 2024 Apr 20:S0302-2838(24)02310-8. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
129. CARDONA ORTEGON JD, Campana Perilla LA, Olarte Bermudez LM
     Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial. Eur Urol 2024;85:105-11
     Eur Urol. 2024 Apr 20:S0302-2838(24)02315-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
130. CORNFORD P, van den Bergh RCN, Briers E, Van den Broeck T, et al
     EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
     Eur Urol. 2024 Apr 12:S0302-2838(24)02254-1. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
131. GRABBERT M, Liakos N, Gratzke C
     Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
     Eur Urol. 2024 Apr 11:S0302-2838(24)02258-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
132. RUSH HL, Gilbert DC, Langley RE
     Re: Bertrand Tombal, Sean Collins, Alicia K. Morgans, et al. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. Eur Urol 2023;84:579-87.
     Eur Urol. 2024 Apr 6:S0302-2838(24)02251-6. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
133. ROY S, Fervaha G, Spratt DE, Sun Y, et al
     Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
     Eur Urol. 2024 Apr 2:S0302-2838(24)02239-5. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
134. ROY S, Saad F, Malone S, Agarwal N, et al
     Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
     Eur Urol. 2024;85:398-400.
     PubMed    
     
     
     
135. O'CALLAGHAN M, Bulamu N, Gormly K, Jay A, et al
     Re: Prevalence of MRI Lesions in Men Responding to a GP-led Invitation for a Prostate Health Check: A Prospective Cohort Study.
     Eur Urol. 2024;85:395.
     PubMed    
     
     
     March 2024
136. ENGLMAN C, Maffei D, Allen C, Kirkham A, et al
     PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer.
     Eur Urol. 2024 Mar 30:S0302-2838(24)02232-2. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
137. LOGOTHETIS CJ, Hahn AW
     Reply to Richard J. Wassersug, Paul F. Schellhammer, and Erik Wibowo's Letter to the Editor re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024
     Eur Urol. 2024 Mar 26:S0302-2838(24)02240-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
138. WASSERSUG RJ, Schellhammer PF, Wibowo E
     Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
     Eur Urol. 2024 Mar 26:S0302-2838(24)02233-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
139. WINDISCH O, Valerio M
     Re: Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
     Eur Urol. 2024 Mar 26:S0302-2838(24)02208-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
140. DE MEERLEER G, Joniau S, Benijts J, Rans K, et al
     Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not.
     Eur Urol. 2024 Mar 22:S0302-2838(24)02238-3. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
141. BURGER M
     Re: First-in-human Evaluation of a Prostate-specific Membrane Antigen-targeted Near-infrared Fluorescent Small Molecule for Fluorescence-based Identification of Prostate Cancer in Patients with High-risk Prostate Cancer Undergoing Robotic-assisted Pro
     Eur Urol. 2024 Mar 22:S0302-2838(24)02205-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
142. NIKITAS J, Rettig M, Shen J, Reiter R, et al
     Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
     Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
143. BABOUDJIAN M, Diamand R, Uleri A, Beauval JB, et al
     Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
     Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
144. CUSSENOT O, Chambaz A, Hamdy FC
     Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur
     Eur Urol. 2024 Mar 15:S0302-2838(24)02139-0. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
145. GARCIA-RUIZ A, Macarro C, Zacchi F, Morales-Barrera R, et al
     Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial.
     Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
146. MOLLER F, Mansson M, Wallstrom J, Hellstrom M, et al
     Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Goteborg-2 Prostate Cancer Screening Trial.
     Eur Urol. 2024 Mar 14:S0302-2838(24)00052-6. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
147. WEBER M, Fendler WP, Ravi Kumar AS, Calais J, et al
     Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
     Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
148. VAUGIER L, Morvan C, Pasquier D, Buthaud X, et al
     Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
     Eur Urol. 2024 Mar 14:S0302-2838(24)02131-6. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
149. NICKOLS NG, Tsai S, Kane N, Tran S, et al
     Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
     Eur Urol. 2024 Mar 14:S0302-2838(24)00079-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
150. MONTIRONI R, Cimadamore A, Giannarini G, Crestani A, et al
     Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population.
     Eur Urol. 2024 Mar 14:S0302-2838(24)02141-9. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
151. FODOR A, Brombin C, Chiti A, Di Muzio N, et al
     Re: Marcin Miszczyk, Pawel Rajawa, Takafumi Yanagisawa, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. In press. https://doi.org/1
     Eur Urol. 2024 Mar 12:S0302-2838(24)02140-7. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
152. SARTOR O
     Prostate-specific Membrane Antigen-targeted Isotope Therapy: Inherent Challenges Owing to Heterogeneity and Clonal Evolution.
     Eur Urol. 2024;85:205-206.
     PubMed    
     
     
     
153. PILATZ A, MacLennan S, van den Bergh RCN, Veeratterapillay R, et al
     Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. 2024;85:99-100.
     Eur Urol. 2024;85:313-314.
     PubMed    
     
     
     February 2024
154. GOLIJANIN B, Mega A, Golijanin D
     Re: Ivo I. de Vos II, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Scr
     Eur Urol. 2024 Feb 29:S0302-2838(24)00081-2. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
155. POPE B, Park G, Lau E, Belic J, et al
     Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer.
     Eur Urol. 2024 Feb 19:S0302-2838(24)00003-4. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
156. FENG D, Wang J, Wu R, Li D, et al
     Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen Deprivation Therapy Against Prostate Cancer.
     Eur Urol. 2024 Feb 17:S0302-2838(24)00069-1. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
157. DE VOS II, Remmers S, Roobol MJ
     Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin's Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renee Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinui
     Eur Urol. 2024 Feb 17:S0302-2838(24)00057-5. doi: 10.1016/j.eururo.2024.
     PubMed    
     
     
     
158. DEIVASIGAMANI S, Kotamarti S, Gupta RT, Polascik TJ, et al
     Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization?
     Eur Urol. 2024;85:180-181.
     PubMed    
     
     
     
159. PREISSER F, Abrams-Pompe RS, Stelwagen PJ, Bohmer D, et al
     European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
     Eur Urol. 2024;85:164-170.
     PubMed     Abstract available
     
     
     
160. MIAN BM
     Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise.
     Eur Urol. 2024;85:99-100.
     PubMed     Abstract available
     
     
     January 2024
161. ARMSTRONG WR, Kishan AU, Booker KM, Grogan TR, et al
     Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
     Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
162. VICKERS AJ, Assel M, Cooperberg MR, Fine SW, et al
     Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.
     Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024.
     PubMed     Abstract available
     
     
     
163. CHI KN, Armstrong AJ, Krause BJ, Herrmann K, et al
     Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
     Eur Urol. 2024 Jan 6:S0302-2838(23)03297-9. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     December 2023
164. LIU M, Chen P, Li T
     Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
     Eur Urol. 2023 Dec 21:S0302-2838(23)03293-1. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
165. HUANG TB, Ding XF
     Re: Matthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial, Eur Urol. In press. htt
     Eur Urol. 2023 Dec 16:S0302-2838(23)03294-3. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
166. ALBERS P, van Poppel H
     Prostate Cancer Screening at its Best: The Swedish Organized Prostate Cancer Testing Program.
     Eur Urol. 2023 Dec 15:S0302-2838(23)03290-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
167. CORPETTI M, Muller C, Beltran H, de Bono J, et al
     Prostate-Specific Membrane Antigen-Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes.
     Eur Urol. 2023 Dec 15:S0302-2838(23)03278-5. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
168. FERNANDEZ-ZAPATA WF, Gandur Quiroga MN, Cardona Maya WD
     Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
     Eur Urol. 2023 Dec 11:S0302-2838(23)03283-9. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
169. RAGGI D, Cigliola A, Mercinelli C, Patane D, et al
     Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials.
     Eur Urol. 2023 Dec 11:S0302-2838(23)03260-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
170. KAPLAN-MARANS E, Zhang TR, Hu JC
     Reply to Fabian Falkenbach, Francesco Sanguedolce, and Lars Budaus's Letter to the Editor re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European A
     Eur Urol. 2023;84:e151.
     PubMed    
     
     
     
171. CAPOGROSSO P, Deho F, Salonia A, Briganti A, et al
     Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534-47.
     Eur Urol. 2023;84:e146.
     PubMed    
     
     
     
172. DJAILEB L, Armstrong WR, Thompson D, Gafita A, et al
     Presurgical (68)Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
     Eur Urol. 2023;84:588-596.
     PubMed     Abstract available
     
     
     
173. SAAD F, Del Rosario P, Clarke NW
     Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespe
     Eur Urol. 2023 Dec 1:S0302-2838(23)03274-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
174. BRATT O, Godtman RA, Jiborn T, Wallstrom J, et al
     Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men.
     Eur Urol. 2023 Dec 1:S0302-2838(23)03272-4. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
175. FALKENBACH F, Sanguedolce F, Budaus L
     Re: Elie Kaplan-Marans, Tenny R. Zhang, Jim C. Hu. Differing Recommendations on Prostate Biopsy Approach to Minimize Infections: An Examination of the European Association of Urology and American Urological Association Guidelines. Eur Urol. 2023;84:44
     Eur Urol. 2023;84:e149-e150.
     PubMed    
     
     
     November 2023
176. GIESEN A, Devlies W, Claessens F, Joniau S, et al
     Re: Abiraterone and Olaparib for Metastatic Castration-resistant Prostate Cancer.
     Eur Urol. 2023 Nov 27:S0302-2838(23)03273-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
177. DING L, Yang B, Yao X
     Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phas
     Eur Urol. 2023 Nov 23:S0302-2838(23)03226-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
178. MUN CHOW K, Zheng So W, Jie Lee H, Lee A, et al
     Corrigendum to "Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic R
     Eur Urol. 2023 Nov 14:S0302-2838(23)03213-X. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
179. MOORE CM, Albertsen P
     When Is It Too Early To Start Prostate Cancer Screening? Reflections on the PROBASE Study Using Magnetic Resonance Imaging for Men Aged 45 Yr with Elevated Prostate-specific Antigen.
     Eur Urol. 2023 Nov 13:S0302-2838(23)03212-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
180. HAMDY FC, Donovan JL
     Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:
     Eur Urol. 2023 Nov 8:S0302-2838(23)03218-9. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
181. MISZCZYK M, Rajwa P, Yanagisawa T, Nowicka Z, et al
     The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
     Eur Urol. 2023 Nov 7:S0302-2838(23)03209-8. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
182. TRUJILLO CG, Pena Rodriguez S, Diaz Ritter C
     Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol. 2023;83:534-47.
     Eur Urol. 2023;84:e116.
     PubMed    
     
     
     
183. FENG T, Ren M, Zhou Z
     Re: Peter Fletcher, Marta De Santis, Simona Ippoliti, et al. Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia. Eur Urol 2023
     Eur Urol. 2023;84:e114.
     PubMed    
     
     
     
184. LINDER S, Severson TM, van der Mijn KJC, Nevedomskaya E, et al
     Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
     Eur Urol. 2023;84:455-460.
     PubMed     Abstract available
     
     
     
185. WERNER RA, Hartrampf PE, Fendler WP, Serfling SE, et al
     Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
     Eur Urol. 2023;84:491-502.
     PubMed     Abstract available
     
     
     October 2023
186. DE VOS II, Remmers S, Hogenhout R, Roobol MJ, et al
     Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
     Eur Urol. 2023 Oct 31:S0302-2838(23)03207-4. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
187. SHAW G, Kelly JD, Roobol MJ
     Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.
     Eur Urol. 2023 Oct 26:S0302-2838(23)03170-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
188. EAPEN RS, Buteau JP, Jackson P, Mitchell C, et al
     Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
     Eur Urol. 2023 Oct 25:S0302-2838(23)03087-7. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
189. SHARMA AD, Good DW, Alan McNeill S
     Re: Patient-reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
     Eur Urol. 2023 Oct 19:S0302-2838(23)03157-3. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
190. BOSCHHEIDGEN M, Albers P, Schlemmer HP, Hellms S, et al
     Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
     Eur Urol. 2023 Oct 18:S0302-2838(23)03158-5. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
191. HERLEMANN A, Cowan JE, Washington SL 3rd, Wong AC, et al
     Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
     Eur Urol. 2023 Oct 17:S0302-2838(23)03155-X. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
192. SORCE G, Mottrie A
     Re: Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study that Challenges the Dogma.
     Eur Urol. 2023 Oct 14:S0302-2838(23)03159-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
193. GANDAGLIA G, Barletta F, Briganti A, Montorsi F, et al
     Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2
     Eur Urol. 2023 Oct 11:S0302-2838(23)03140-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
194. KRAFFT U, Hadaschik BA, Luckerath K, Herrmann K, et al
     A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?
     Eur Urol. 2023 Oct 11:S0302-2838(23)03149-4. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
195. TOMBAL B, Collins S, Morgans AK, Hunsche E, et al
     Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
     Eur Urol. 2023 Oct 11:S0302-2838(23)03099-3. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
196. JUNG J, Kim JH
     Re: Casey Crump, Par Stattin, James D. Brooks, et al. Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study. Eur Urol 2023;84:263-72.
     Eur Urol. 2023 Oct 11:S0302-2838(23)03154-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
197. HICKS RJ
     The Pythia Speaks on Prostate Cancer Diagnosis and Treatment.
     Eur Urol. 2023 Oct 11:S0302-2838(23)03148-2. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
198. KISHAN AU, Valle LF, Marks LS
     Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging-visible Disease in Radiorecurrent Prostate Cancer.
     Eur Urol. 2023 Oct 5:S0302-2838(23)03145-7. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
199. COLE AP, Gupta N, Loeb S
     The Plant-based Prescription: How Dietary Change Can Improve Both Urological and Planetary Health.
     Eur Urol. 2023;84:357-358.
     PubMed     Abstract available
     
     
     
200. HEIJNSDIJK EAM, de Koning HJ
     Wise Prostate-specific Antigen Testing Means a Limited, Risk-adjusted, and Personal Approach.
     Eur Urol. 2023;84:359-360.
     PubMed    
     
     
     September 2023
201. LIGHT A, Kanthabalan A, Otieno M, Pavlou M, et al
     The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial.
     Eur Urol. 2023 Sep 29:S0302-2838(23)03089-0. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
202. LAMBERT E, Roupret M
     Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.
     Eur Urol. 2023 Sep 27:S0302-2838(23)03137-8. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
203. BEATRICI E, Labban M, Stone BV, Filipas DK, et al
     Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base.
     Eur Urol. 2023 Sep 25:S0302-2838(23)03088-9. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
204. PONTES-SILVA A
     Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
     Eur Urol. 2023 Sep 25:S0302-2838(23)03094-4. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
205. ILIE G, Rutledge RDH
     Reply to Andre Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Tr
     Eur Urol. 2023 Sep 22:S0302-2838(23)03091-9. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
206. MAY M, Wolff I, Brookman-May SD
     Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023
     Eur Urol. 2023 Sep 22:S0302-2838(23)03095-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
207. KLOTZ L
     Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.
     Eur Urol. 2023 Sep 22:S0302-2838(23)03080-4. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
208. OPREA-LAGER DE, MacLennan S, Bjartell A, Briganti A, et al
     European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
     Eur Urol. 2023 Sep 22:S0302-2838(23)03092-0. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
209. ILIE G, Rutledge RDH
     Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Un
     Eur Urol. 2023 Sep 22:S0302-2838(23)03093-2. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
210. VAN POPPEL H, Roobol MJ, Chandran A
     Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U.
     Eur Urol. 2023 Sep 11:S0302-2838(23)03023-3. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
211. MICHEL MC
     Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening.
     Eur Urol. 2023 Sep 9:S0302-2838(23)03081-6. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     
212. ROCCO B, Sighinolfi MC
     Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547-58.
     Eur Urol. 2023 Sep 6:S0302-2838(23)03069-5. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     
     August 2023
213. PAPACHRISTODOULOU A, Heidegger I, Virk RK, Di Bernardo M, et al
     Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.
     Eur Urol. 2023 Aug 31:S0302-2838(23)03016-6. doi: 10.1016/j.eururo.2023.
     PubMed     Abstract available
     
     
     
214. HAMDY FC, Donovan JL
     Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-
     Eur Urol. 2023 Aug 31:S0302-2838(23)03070-1. doi: 10.1016/j.eururo.2023.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.